TAFASITAMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 00:22:39 GMT 2025` Edited by `admin` on `Wed Apr 02 00:22:39 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1-2-KAPPA
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	QQA9MLH692
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

MOR-00208

Preferred Name

English

TAFASITAMAB

Official Name

English

TAFASITAMAB [MI]

Common Name

English

MOR-208

Common Name

English

XMAB5574

Common Name

English

TAFASITAMAB [USAN]

Common Name

English

HUMANIZED FC ENGINEERED MONOCLONAL ANTIBODY AGAINST CD19

Common Name

English

IMMUNOGLOBULIN, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL MOR00208 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MOR00208 .KAPPA.-CHAIN, DIMER

Common Name

English

MOR00208

Code

English

Tafasitamab [WHO-DD]

Common Name

English

XMAB-5574

Common Name

English

tafasitamab [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

456014

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

EU-Orphan Drug

EU/3/17/1962

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

FDA ORPHAN DRUG

427914

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

Code System Code Type Description

WIKIPEDIA

Tafasitamab

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

SMS_ID

100000183311

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

DRUG BANK

DB15044

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

CAS

1422527-84-1

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

RXCUI

2387211

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

MERCK INDEX

m12232

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

INN

10835

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

NCI_THESAURUS

C95768

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

DAILYMED

QQA9MLH692

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

USAN

GH-86

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

FDA UNII

QQA9MLH692

Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025

PRIMARY

From	To
1_22	1_96
1_148	1_204
1_265	1_325
1_371	1_429
1_224	3_219
1_230	2_230
1_233	2_233
2_22	2_96
2_148	2_204
2_265	2_325
2_371	2_429
2_224	4_219
3_23	3_93
3_139	3_199
4_23	4_93
4_139	4_199

Glycosylation Link Type	Site
N	1_301
N	2_301

Related Record Type Details


					IYZ9TI08W3

B-LYMPHOCYTE ANTIGEN CD19

TARGET->LIGAND

Qualification:

Scientific Literature

TAFASITAMAB-CXIX

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					QQA9MLH692

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL